XPOVIO® (selinexor) has made a significant step in Taiwan by becoming the first approved XPO1 inhibitor for adults with relapsed/refractory multiple myeloma (R/R MM). This approval means it will be included in Taiwan’s public health insurance from March 1, 2025. Previously, it gained reimbursement in other countries, including mainland China, South Korea, Australia, and Singapore, making Taiwan the fifth market in the Asia-Pacific (APAC) region to offer this coverage.
Multiple myeloma is a type of cancer affecting plasma cells, and it poses serious treatment challenges. In Taiwan, about 700 to 800 new cases and around 400 deaths occur each year due to this disease. Patients often face a high likelihood of relapse and limited treatment options. The inclusion of XPOVIO® in public health insurance can relieve some financial stress for these patients and their families.
XPOVIO® works differently from many other treatments. As the first oral XPO1 inhibitor, it helps inhibit the growth of cancer cells by promoting the accumulation of tumor-fighting proteins within cells. This unique mechanism allows it to target multiple pathways that contribute to tumor growth, making it an important option for patients who have already undergone several lines of therapy.
Antengene Corporation, the developer of XPOVIO®, is also exploring other uses for the drug. They are working on combining it with different therapies for treating various cancers, including myelofibrosis and endometrial cancer. Antengene’s goal is to bring innovative cancer treatments to more patients across countries.
Antengene is dedicated to advancing cancer therapy. Their portfolio includes several oncology treatments, reflecting their commitment to improving patient outcomes worldwide. Since its founding, Antengene has received multiple approvals for new drugs in the U.S. and Asia. Their efforts highlight the need for innovative and accessible cancer treatments for patients everywhere.
Source link
Antengene Corporation Limited
